文献速递中医内科中药与中成药合理使用

中药汤剂治疗偏头痛疗效与安全性的贝叶斯网络Meta分析

Efficacy and safety of Chinese botanical drug decoctions for migraine: a Bayesian network meta-analysis.
PubMed 文献 · Front Pharmacol · 2026-05-01

结果显示散偏汤可能对降低VAS评分更有利,血府逐瘀汤在减少头痛发作频率和持续时间方面排名最高,通窍活血汤基于SUCRA排名总体疗效最优。

要点

  • 散偏汤可能更利于降低偏头痛患者VAS疼痛评分。
  • 血府逐瘀汤在减少头痛发作频率和持续时间方面排名最高。
  • 通窍活血汤基于SUCRA排名总体疗效最优,但证据需谨慎解读。

核心结论

  • 中药汤剂可能改善偏头痛相关结局,其中散偏汤可能更利于降低疼痛强度,血府逐瘀汤可能减少发作频率和持续时间,通窍活血汤SUCRA排名总体最优。
  • 因研究质量差异和间接比较性质,上述结论应谨慎解读。

研究设计与样本

  • 纳入57项随机对照试验,共6005例患者,使用ROB 2.0评估偏倚风险,R软件gemtc包运行4条马尔可夫链,迭代50000次,预热20000次。

主要发现

  • 散偏汤与VAS评分更大程度降低相关。
  • 血府逐瘀汤在减少头痛频率和持续时间方面排名最高。
  • 通窍活血汤基于SUCRA排名具有最高概率成为最有效干预之一。

关键数值与推荐

  • 共纳入57项随机对照试验,涉及6005例患者。
  • 使用SUCRA估计治疗排名概率。

临床怎么用

  • 临床可结合偏头痛患者具体结局(疼痛强度、发作频率、持续时间)参考相应汤剂排名,但需考虑证据不确定性。
  • 处方决策应个体化,并关注研究质量差异带来的间接比较局限性。

局限性

  • 研究间存在质量差异。
  • 网络Meta分析包含间接比较,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Migraine is a common neurological disorder that substantially affects patients' quality of life. Chinese botanical drug decoctions are used in migraine management; however, the comparative efficacy and safety of different decoctions remain unclear. Therefore, this study aimed to compare multiple Chinese botanical drug decoctions for migraine using a Bayesian network meta-analysis. METHODS: Seven electronic databases (PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP) were systematically searched from inception to 20 October 2025. Randomized controlled trials evaluating Chinese botanical drug decoctions for migraine were included. Risk of bias was assessed using the ROB 2.0 tool. A Bayesian network meta-analysis was conducted using R software with the gemtc package. Four Markov chains were run simultaneously, with 50,000 iterations and a burn-in period of 20,000 iterations to ensure model convergence. Treatment ranking probabilities were estimated using the surface under the cumulative ranking curve (SUCRA). RESULTS: A total of 57 randomized controlled trials involving 6,005 patients were included. Network meta-analysis suggested that Sanpian Decoction (SPT) was associated with greater reductions in visual Analog Scale (VAS) scores, while Xuefu Zhuyu Decoction (XFZYT) ranked highest for reducing headache frequency and duration. Tongqiao Huoxue Decoction (TQHXT) had the highest probability of being among the most effective interventions based on SUCRA rankings. CONCLUSION: Chinese botanical drug decoctions may be associated with improvements in migraine-related outcomes. Among the evaluated interventions, SPT may be associated with greater reductions in pain intensity, XFZYT may be associated with reductions in attack frequency and duration, and TQHXT had the highest SUCRA-based ranking for overall efficacy. However, these findings should be interpreted with caution due to variability in study quality and the indirect nature of comparisons. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251176748.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang F, Wang H, Yang D, et al. Efficacy and safety of Chinese botanical drug decoctions for migraine: a Bayesian network meta-analysis. Front Pharmacol. 2026. PMID: 42147339. doi:10.3389/fphar.2026.1799920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。